Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) was the target of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 30,000 shares, an increase of 98.7% from the February 13th total of 15,100 shares. Based on an average daily trading volume, of 362,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 5.4% of the company’s stock are sold short.
Bluejay Diagnostics Stock Performance
Shares of NASDAQ:BJDX traded up $0.06 during mid-day trading on Friday, hitting $4.04. 24,422 shares of the company traded hands, compared to its average volume of 190,710. The firm has a market cap of $2.23 million, a P/E ratio of 0.00 and a beta of 0.38. Bluejay Diagnostics has a 52-week low of $3.03 and a 52-week high of $349.64. The firm’s 50 day simple moving average is $3.76 and its 200 day simple moving average is $4.93.
Institutional Investors Weigh In On Bluejay Diagnostics
A hedge fund recently raised its stake in Bluejay Diagnostics stock. Anson Funds Management LP raised its holdings in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Free Report) by 359.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 319,280 shares of the company’s stock after purchasing an additional 249,770 shares during the quarter. Anson Funds Management LP owned 1.93% of Bluejay Diagnostics worth $41,000 at the end of the most recent quarter. 18.47% of the stock is owned by institutional investors.
About Bluejay Diagnostics
Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.
Featured Stories
- Five stocks we like better than Bluejay Diagnostics
- What is an Earnings Surprise?
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- ESG Stocks, What Investors Should Know
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
